Overview

CLINICAL RESEARCH PROTOCOL [A Phase I, Single-arm, Open-label, Dose-escalation Clinical Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult Volunteers]

Status:
COMPLETED

Trial end date:
2025-08-31

Target enrollment:

Participant gender:

Summary

This Phase I clinical study is designed to evaluate the safety and determine the maximum tolerated dose (MTD) of Orialpha (BD-C) in healthy adult volunteers.

Phase:

PHASE1

Details

Lead Sponsor:

Oriplantee Company Limited

Collaborator:

Vietstar Biomedical Research